AVITA Medical, Inc. (RCEL)
- Previous Close
8.35 - Open
7.94 - Bid 8.66 x 100
- Ask 8.77 x 100
- Day's Range
7.51 - 8.83 - 52 Week Range
7.51 - 21.70 - Volume
508,060 - Avg. Volume
256,603 - Market Cap (intraday)
224.973M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.40 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.40
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
www.avitamedical.comRecent News: RCEL
Performance Overview: RCEL
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RCEL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RCEL
Valuation Measures
Market Cap
215.43M
Enterprise Value
168.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.22
Price/Book (mrq)
4.39
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-88.41%
Return on Assets (ttm)
-32.80%
Return on Equity (ttm)
-81.39%
Revenue (ttm)
50.7M
Net Income Avi to Common (ttm)
-44.82M
Diluted EPS (ttm)
-1.40
Balance Sheet and Cash Flow
Total Cash (mrq)
68.18M
Total Debt/Equity (mrq)
134.59%
Levered Free Cash Flow (ttm)
--
Research Analysis: RCEL
Company Insights: RCEL
RCEL does not have Company Insights